Regimen That Reduces Cranial Radiation, HSCT Yields Promising Outcomes in ALL-T11
Researchers sought to determine the efficacy of a combination nelarabine, intensified L-asparaginase, and protracted intrathecal therapy among patients with ALL-T11.
Researchers sought to determine the efficacy of a combination nelarabine, intensified L-asparaginase, and protracted intrathecal therapy among patients with ALL-T11.
Researchers investigated whether adding venetoclax to ibrutinib and obinutuzumab would improve survival and allow for discontinuation of treatment in older patients with CLL.
Researchers sought to determine if a chemotherapy-free regimen including inotuzumab ozogamicin and blinatumomab would be effective in elderly patients with B-cell ALL.
Researchers sought to determine whether assessment of MRD using flow cytometry would improve risk stratification in pediatric ALL.
Researchers sought to determine long-term outcomes in children after relapse following CD19-directed CAR-T therapy for B-ALL.
Researchers sought to determine the impact of donor age on survival in patients with ALL who undergo HCT with PTCy for GVHD prophylaxis.
Researchers sought to determine whether adding quizartinib to standard chemotherapy would improve survival in patients with newly diagnosed FLT3-ITD-positive AML.
Researchers sought to determine whether a clinicogenomic analysis of T-ALL would be able to confirm poor outcomes despite treatment with chemotherapy and HSCT.
Researchers sought to determine the proportion of potentially eligible patients with high-risk MDS or AML who are considered for HCT.
Researchers sought to determine clinical indicators that are associated with ATO-induced hepatotoxicity in patients with APL.